Becton, Dickinson and Company (NYSE:BDX) Shares Bought by Sequoia Financial Advisors LLC

Sequoia Financial Advisors LLC grew its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 55.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 5,609 shares of the medical instruments supplier’s stock after purchasing an additional 2,005 shares during the quarter. Sequoia Financial Advisors LLC’s holdings in Becton, Dickinson and Company were worth $1,368,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in BDX. RVW Wealth LLC acquired a new position in shares of Becton, Dickinson and Company during the 3rd quarter valued at about $52,000. Vest Financial LLC raised its holdings in Becton, Dickinson and Company by 27.5% in the 4th quarter. Vest Financial LLC now owns 103,004 shares of the medical instruments supplier’s stock valued at $25,115,000 after buying an additional 22,207 shares during the period. M. Kulyk & Associates LLC raised its holdings in Becton, Dickinson and Company by 5.1% in the 3rd quarter. M. Kulyk & Associates LLC now owns 16,640 shares of the medical instruments supplier’s stock valued at $4,302,000 after buying an additional 809 shares during the period. SG Americas Securities LLC raised its holdings in Becton, Dickinson and Company by 69.4% in the 4th quarter. SG Americas Securities LLC now owns 15,113 shares of the medical instruments supplier’s stock valued at $3,685,000 after buying an additional 6,190 shares during the period. Finally, BKM Wealth Management LLC purchased a new stake in Becton, Dickinson and Company in the 4th quarter valued at about $1,043,000. Institutional investors and hedge funds own 86.97% of the company’s stock.

Insider Transactions at Becton, Dickinson and Company

In other news, SVP Thomas J. Spoerel sold 282 shares of the business’s stock in a transaction dated Thursday, March 14th. The stock was sold at an average price of $238.29, for a total transaction of $67,197.78. Following the completion of the transaction, the senior vice president now directly owns 2,276 shares of the company’s stock, valued at $542,348.04. The sale was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 0.31% of the company’s stock.

Analyst Ratings Changes

BDX has been the topic of several research analyst reports. Raymond James boosted their price objective on shares of Becton, Dickinson and Company from $269.00 to $275.00 and gave the company an “outperform” rating in a report on Wednesday, January 3rd. Barclays boosted their price objective on shares of Becton, Dickinson and Company from $301.00 to $305.00 and gave the company an “overweight” rating in a report on Monday, February 5th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, Becton, Dickinson and Company currently has an average rating of “Moderate Buy” and an average target price of $280.00.

Becton, Dickinson and Company Stock Down 2.3 %

Shares of NYSE:BDX opened at $235.17 on Friday. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.08 and a quick ratio of 0.64. The firm has a market capitalization of $67.94 billion, a PE ratio of 55.73, a price-to-earnings-growth ratio of 1.99 and a beta of 0.43. The firm’s 50-day moving average is $240.64 and its two-hundred day moving average is $243.22. Becton, Dickinson and Company has a 1 year low of $229.85 and a 1 year high of $287.32.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings results on Thursday, February 1st. The medical instruments supplier reported $2.68 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.39 by $0.29. The company had revenue of $4.71 billion for the quarter, compared to analyst estimates of $4.73 billion. Becton, Dickinson and Company had a net margin of 6.44% and a return on equity of 13.57%. The business’s revenue for the quarter was up 2.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.98 earnings per share. Analysts predict that Becton, Dickinson and Company will post 12.94 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, March 29th. Stockholders of record on Friday, March 8th were given a dividend of $0.95 per share. This represents a $3.80 dividend on an annualized basis and a dividend yield of 1.62%. The ex-dividend date of this dividend was Thursday, March 7th. Becton, Dickinson and Company’s dividend payout ratio is presently 90.05%.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.